EPP Treatment News

A new drug that could prevent or reduce sun sensitivity in EPP patients has received Investigational New Drug (IND) status from the FDA.

Afamelanotide, from Australian maker Clinuvel Pharmaceuticals, received Orphan Drug Designation (ODD) from the FDA last July and has been undergoing advanced clinical trials in Europe.

Dr. Joseph Bloomer will discuss the prospects for U.S. studies of Afamelanotide on the EPP Conference Call Saturday July 25, 2009. Read more news from Clinuvel about the medication's regulatory history so far:

FDA Allows IND Status for Clinuvel's Afamelanotide
Clinuvel Announces Positive Phase III Interim Results for EPP